A detailed history of Morris Capital Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Morris Capital Advisors, LLC holds 35,648 shares of BMY stock, worth $2.06 Million. This represents 2.39% of its overall portfolio holdings.

Number of Shares
35,648
Previous 36,106 1.27%
Holding current value
$2.06 Million
Previous $2.78 Million 8.85%
% of portfolio
2.39%
Previous 2.48%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 26, 2022

SELL
$0.13 - $76.84 $59 - $35,192
-458 Reduced 1.27%
35,648 $2.53 Million
Q2 2022

Jul 15, 2022

BUY
$72.62 - $79.98 $51,342 - $56,545
707 Added 2.0%
36,106 $2.78 Million
Q1 2022

May 09, 2022

BUY
$61.48 - $73.72 $503,398 - $603,619
8,188 Added 30.09%
35,399 $2.59 Million
Q4 2021

Feb 09, 2022

SELL
$53.63 - $62.52 $494,575 - $576,559
-9,222 Reduced 25.31%
27,211 $1.7 Million
Q3 2021

Oct 22, 2021

SELL
$59.17 - $69.31 $78,696 - $92,182
-1,330 Reduced 3.52%
36,433 $2.16 Million
Q2 2021

Jul 15, 2021

SELL
$61.91 - $67.42 $33,369 - $36,339
-539 Reduced 1.41%
37,763 $2.52 Million
Q1 2021

Apr 16, 2021

SELL
$59.34 - $66.74 $57,263 - $64,404
-965 Reduced 2.46%
38,302 $2.42 Million
Q4 2020

Jan 19, 2021

SELL
$57.74 - $65.43 $232,692 - $263,682
-4,030 Reduced 9.31%
39,267 $2.44 Million
Q3 2020

Oct 19, 2020

SELL
$57.43 - $63.64 $159,310 - $176,537
-2,774 Reduced 6.02%
43,297 $2.61 Million
Q2 2020

Jul 23, 2020

SELL
$54.82 - $64.09 $153,715 - $179,708
-2,804 Reduced 5.74%
46,071 $2.71 Million
Q1 2020

May 07, 2020

BUY
$46.4 - $67.43 $320,531 - $465,806
6,908 Added 16.46%
48,875 $2.72 Million
Q4 2019

Jan 31, 2020

BUY
$49.21 - $64.19 $2.07 Million - $2.69 Million
41,967 New
41,967 $2.69 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Morris Capital Advisors, LLC Portfolio

Follow Morris Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morris Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Morris Capital Advisors, LLC with notifications on news.